June 22, 2024

Oncology Molecular Diagnostic Market Size to Hit USD 7.71 Bn By 2033

The global oncology molecular diagnostic market size was valued at USD 2.45 billion in 2023 and is expected to grow around USD 7.71 billion by 2033 with a CAGR of 12.20%  from 2024 to 2033.

Key Takeaways

  • North America contributed more than 41% of the market share in 2023.
  • Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2033.
  • By type, the breast cancer segment generated over 22% of the market share in 2023.
  • By type, the liver cancer segment is anticipated to grow at a remarkable CAGR of 13.9% between 2024 and 2033.
  • By technology, the polymerase chain reaction (PCR) segment generated over 32% of the market share in 2023.
  • By technology, the sequencing segment is expected to expand at the fastest CAGR over the projected period.
  • By product, the reagents segment generated over 59% of market share in 2023.
  • By product, the instruments segment is expected to expand at the fastest CAGR over the projected period.

Oncology Molecular Diagnostic Market Size 2024 To 2033

The Oncology Molecular Diagnostic Market is a dynamic sector within the broader healthcare industry, specializing in the diagnosis and assessment of cancer through molecular techniques. This market plays a crucial role in providing precise and personalized information about the genetic makeup of tumors, aiding in treatment decisions and patient care. The integration of molecular diagnostics into oncology has significantly transformed the landscape of cancer diagnosis and management.

Get a Sample:  https://www.precedenceresearch.com/sample/3677

Growth Factors:

Several factors contribute to the robust growth of the Oncology Molecular Diagnostic Market. Advancements in genomic technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), have empowered healthcare professionals to analyze genetic alterations with unprecedented accuracy. The increasing prevalence of cancer cases globally has also driven the demand for reliable and efficient diagnostic tools, fostering market expansion. Additionally, a growing awareness of the benefits of early cancer detection and the rising trend of personalized medicine further propel the market’s growth.

Oncology Molecular Diagnostic Market  Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 12.20%
Global Market Size in 2023 USD 2.45 Billion
Global Market Size by 2033 USD 7.71 Billion
U.S. Market Size in 2023 USD 0.70 Billion
U.S. Market Size by 2033 USD 2.25 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Type, By Technology and By Product
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Flexitank Market Size To Rise USD 10.25 Billion By 2033

Market Dynamics

Drivers:

Key drivers influencing the Oncology Molecular Diagnostic Market include the rising incidence of various cancer types, prompting the need for precise and rapid diagnostic solutions. The increasing adoption of targeted therapies and immunotherapies, which often require molecular profiling for treatment decisions, is a significant driver. Collaborations between diagnostic companies and pharmaceutical firms to develop companion diagnostics for specific therapies also contribute to market growth.

Opportunities:

The Oncology Molecular Diagnostic Market presents exciting opportunities for innovation and expansion. Ongoing research and development efforts to identify novel biomarkers and therapeutic targets open doors for the introduction of new diagnostic assays and technologies. Furthermore, the integration of artificial intelligence (AI) and machine learning in data interpretation enhances the potential for more accurate and efficient molecular diagnostics. Emerging markets, with a growing emphasis on healthcare infrastructure development, offer untapped opportunities for market players to expand their reach.

Challenges:

Despite its promising outlook, the Oncology Molecular Diagnostic Market faces challenges. The high cost associated with molecular diagnostic tests poses a barrier to widespread adoption, particularly in resource-limited settings. Regulatory complexities and the need for rigorous validation of diagnostic assays add to the challenges. Additionally, ensuring the standardization of molecular testing procedures and managing the vast amounts of data generated in genomic analysis present ongoing hurdles for industry stakeholders. Overcoming these challenges is crucial for the sustained growth and advancement of the market.

Reasons to Purchase this Report:

  • Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
  • In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
  • Market size in USD million and volume in million units provided for each segment and sub-segment.
  • Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
  • Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Recent Developments in the Oncology Molecular Diagnostic Market

  • In December 2020, Veracyte Inc. and Bayer AG initiated a collaboration to enhance the Precision Oncology Patient Identification Program, specifically focusing on thyroid cancer. This partnership aims to utilize Veracyte’s Afirma Xpression Atlas (XA) for testing, identifying genomic drivers in tumor cells. The program is anticipated to benefit patients with advanced thyroid cancer by enabling personalized treatment strategies based on biomarker-driven therapies.
  • In February 2020, Danaher, through its subsidiary Cepheid, announced a collaboration with Sherlock Biosciences to explore the development of innovative molecular diagnostic tests using CRISPR technology. The focus of this collaboration extends to oncology and infectious diseases, signaling a joint effort to advance groundbreaking diagnostic solutions for improved patient care and disease management.

Oncology Molecular Diagnostic Market Companies

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Bio-Rad Laboratories, Inc.
  • Genomic Health, Inc.
  • Myriad Genetics, Inc.
  • Agilent Technologies, Inc.
  • Siemens Healthineers
  • Danaher Corporation (Cepheid)
  • Sysmex Corporation
  • Hologic, Inc.
  • Guardant Health, Inc.
  • Foundation Medicine, Inc.

Segments Covered in the Report:

By Type

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Blood Cancer
  • Kidney Cancer
  • Other Cancer

By Technology

  • PCR
  • In Situ Hybridization
  • INAAT
  • Chips and Microarrays
  • Mass Spectrometry
  • Sequencing
  • TMA
  • Others

By Product

  • Instruments
  • Reagents
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oncology Molecular Diagnostic Market 

5.1. COVID-19 Landscape: Oncology Molecular Diagnostic Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oncology Molecular Diagnostic Market, By Type

8.1. Oncology Molecular Diagnostic Market Revenue and Volume, by Type, 2024-2033

8.1.1 Breast Cancer

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Prostate Cancer

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Liver Cancer

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Lung Cancer

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. Lung Cancer

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

8.1.8. Blood Cancer

8.1.8.1. Market Revenue and Volume Forecast (2021-2033)

8.1.9. Kidney Cancer

8.1.9.1. Market Revenue and Volume Forecast (2021-2033)

8.1.10. Other Cancer

8.1.10.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Oncology Molecular Diagnostic Market, By February

9.1. Oncology Molecular Diagnostic Market Revenue and Volume, by February, 2024-2033

9.1.1. Cathode

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Anode

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Electrolyte

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Separator

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Oncology Molecular Diagnostic Market, By March 

10.1. Oncology Molecular Diagnostic Market Revenue and Volume, by March, 2024-2033

10.1.1. Consumer

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Automotive

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Industrial

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Cheese

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

10.1.5. Others

10.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Oncology Molecular Diagnostic Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by March (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by February (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by March (2021-2033)

Chapter 12. Company Profiles

12.1. Roche Diagnostics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Abbott Laboratories

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Thermo Fisher Scientific Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Qiagen N.V.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bio-Rad Laboratories, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Genomic Health, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Myriad Genetics, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Agilent Technologies, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Siemens Healthineers

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/


Leave a Reply

Your email address will not be published. Required fields are marked *